ALK-mutated non-small-cell lung cancer: A new strategy for cancer treatment

Lung

Volumn 190, Issue 4, 2012, Pages 381-388

  Cabezón Gutiérrez, Luis ^a,b   Khosravi Shahi, Parham ^b   Diaz Muñoz De La Espada, Victor Manuel ^c   Carrión Galindo, Jose Rafael ^c   Eraña Tomás, Itziar ^a   Castro Otero, María ^a  

^a HOSPITAL UNIVERSITARIO DE TORREJÓN   (Spain)

^b Calle Mendez ^*  (Spain)

^c Hospital Del Sureste   (Spain)

Author keywords

Anaplastic lymphoma kinase; Crizotinib; Non small cell lung carcinoma; Tyrosine kinase inhibitor

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; AP 26113; CRIZOTINIB; DOCETAXEL; GSK 1838705A; NMS E628; PEMETREXED; PROTEIN TYROSINE KINASE INHIBITOR; TAE 684; UNCLASSIFIED DRUG;

CANCER SURVIVAL; CANCER THERAPY; CELL PROLIFERATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG HALF LIFE; ENZYME ACTIVATION; GENE MUTATION; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PATHOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; VISUAL DISORDER;

CARCINOMA, NON-SMALL-CELL LUNG; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TRANSLOCATION, GENETIC;

EID: 84864358468     PISSN: 03412040     EISSN: 14321750     Source Type: Journal    
DOI: 10.1007/s00408-012-9391-y     Document Type: Review

References (51)

1. American Cancer Society. Cancer Facts and Figures 2011. Atlanta, GA: American Cancer Society, 2011. http://www.cancer.org/Research/Cancer Facts Figures/Cancer Facts Figures/cancer-facts-figures-2011. Accessed 27 July 2011
2. Webb TR, Slavish J, George RE, Look AT et al (2009) Ana-plastic lymphoma kinase: role in cancer pathogenesis and small molecule inhibitor development for therapy. Expert Rev Anti-cancer Ther 9:331-356
3. Lin E, Li L, Guan Y, Soriano R et al (2009) Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers. Mol Cancer Res 7:1466-1476
4. Fukuyoshi Y, Inoue H, Kita Y, Utsunomiya T, Ishida T, Mori M (2008) EML4-ALK fusion transcript is not found in gastrointes-tinal and breast cancers. Br J Cancer 98:1536-1539 (Pubitemid 351652334)
5. Janoueix-Lerosey I, Lequin D, Brugieres L et al (2008) Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455:967-970
6. Soda M, Choi YL, Enomoto M, Takada S et al (2007) Identifi-cation of the transforming EML4-ALK fusion gene in nonsmall-cell lung cancer. Nature 448:561-566 (Pubitemid 47206930)
7. Morris SW, Kirstein MN, Valentine MB et al (1995) Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 267(5196):316-317
8. Li R, Morris SW (2008) Development of anaplastic lymphoma kinase (ALK) small-molecule inhibitors for cancer therapy. Med Res Rev 28(3):372-412 (Pubitemid 351590540)
9. Kelleher FC, Mc Dermott R (2010) The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene. Eur J Cancer 46(13):2357-2368
10. Stoica GE, Kuo A, Aigner A, Sunitha I, Souttou B, Malerczyk C et al (2001) Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin. J Biol Chem 276: 16772-16779
11. Stoica GE, Kuo A, Powers C, Bowden ET, Sale EB, Riegel AT et al (2002) Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types. J Biol Chem 277:35990-35998
12. Tartari CJ, Gunby RH, Coluccia AM et al (2008) Characteriza-tion of some molecular mechanisms governing autoactivation of the catalytic domain of the anaplastic lymphoma kinase. J Biol Chem 283:3743-3750
13. Lee CC, Jia Y, Li N, Sun X, Ng K, Ambing E et al (2010) Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain. Biochem J 430:425-437
14. Wellstein A, Toretsky JA (2011) Hunting ALK to feed targeted cancer therapy. Nat Med 17(3):290-291
15. Mossé YP, Laudenslager M, Longo L et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455(7215):930-935
16. Chen Z, Sasaki T, Tan X et al (2010) Inhibition of ALK, PI3K/ MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Res 70(23):9827-9836
17. Palmer RH, Vernersson E, Grabbe C, Hallberg B (2009) Ana-plastic lymphoma kinase: signalling in development and disease. Biochem J 420:345-361
18. Koivunen JP, Mermel C, Zejnullahu K et al (2008) EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 14:4275-4283
19. Shinmura K, Kageyama S, Tao H et al (2008) EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61:163-169
20. Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K et al (2009) KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143-3149
21. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H et al (2007) Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 131:1190-1203 (Pubitemid 350235027)
22. Ladanyi M, Cavalchire G (1996) Molecular variant of the NPM-ALK rearrangement of Ki-1 lymphoma involving a cryptic ALK splice site. Genes Chromosomes Cancer 15:173-177
23. De Castro-Carpeño J, Perona R, Belda-Iniesta C (2011) Treat-ment for ALK-mutated non-small-cell lung cancer: a new miracle in the research race. Clin Transl Oncol 13:774-779
24. Kasprzycka M, Marzec M, Liu X, Zhang Q, Wasik MA (2006) Nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) oncoprotein induces the T regulatory cell phenotype by activating STAT3. Proc Natl Acad Sci USA 103:9964-9969 (Pubitemid 43993606)
25. Chiarle R, Simmons WJ, Cai H et al (2005) Stat3 is required for ALK-mediated lymphomagenesis and provides a possible thera-peutic target. Nat Med 11:623-629 (Pubitemid 40868302)
26. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J (2000) Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidyl-inositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 96: 4319-4327
27. Zou HY, Li Q, Lee JH et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67:4408-4417 (Pubitemid 46815090)
28. Armstrong F, Duplantier MM, Trempat P et al (2004) Differential effects of X-ALK fusion proteins on proliferation, transforma-tion, and invasion properties of NIH3T3 cells. Oncogene 23: 6071-6082 (Pubitemid 39178860)
29. Mc Dermott U, Iafrate AJ, Gray NS et al (2008) Genomic alter-ations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 68:3389-3395
30. Christensen JG, Zou HY, Arango ME et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of ana-plastic large-cell lymphoma. Mol Cancer Ther 6:3314-3322
31. Perner S, Wagner PL, Demichelis F et al (2008) EML4-ALK fusion lung cancer: a rare acquired event. Neoplasia 10:298-302 (Pubitemid 351328588)
32. Salido M, Pijuan L, Martínez-Aviles L et al (2011) Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 6:21-27
33. Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lym-phoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693-1703
34. Camidge DR, Bang YJ, Kwak EL et al. (2011) Progression-free survival (PFS) from a phase 1 study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 29(ASCO Meeting Abstr Suppl): Abstr 2501
35. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erl-otinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132 (Pubitemid 41058344)
36. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589-1597 (Pubitemid 41079796)
37. Shaw AT, Yeap BY, Solomon BJ et al (2011) Effect ofcrizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12(11):1004-1012
38. Choi YL, Soda M, Yamashita Y et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734-1739
39. Bossi RT, Saccardo MB, Ardini E et al (2010) Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 49:6813-6825
40. Heuckmann JM, Hölzel M, Sos ML et al (2011) ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 17(23):7394-7401
41. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L et al (2007) Identification of NVP-TAE684, a potent, selective, and effica-cious inhibitor of NPMALK. Proc Natl Acad Sci USA 104:270-275
42. Van Roosbroeck K, Cools J, Dierickx D et al (2010) ALK-positive large B-cell lymphomas with cryptic SEC31A-ALK and NPM1-ALK fusions. Haematologica 95:509-513
43. Sabbatini P, Korenchuk S, Rowand JL et al (2009) GSK1838705A inhibits the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase and shows antitumor activity in experimental models of human cancers. Mol Cancer Ther 8: 2811-2820
44. Rabindran SK, Sabbatini P, Korenchuk et al. (2010) Character-ization of GSK1838705A, a small molecule inhibitor of the insulin-like growth factor-1 receptor and anaplastic lymphoma kinase that delays growth of IGF-1R-dependent tumors and causes regression of ALK-dependent tumors in vivo. Proceedings of the 100th annual meeting of the American association for cancer research (AACR), Denver, CO, 27-30 September 2010
45. Pulford K, Morris SW, Turturro F (2004) Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 199: 330-358 (Pubitemid 38580430)
46. Ardini E, Menichincheri M, De Ponti C et al. (2009) Character-ization of NMS-E628, a small molecule inhibitor of anaplastic lymphoma kinase with antitumor efficacy in ALK-dependent lymphoma and non-small cell lung cancer models. Mol Cancer Therapeutics 8(12 Suppl 1): abstr 243
47. Shakespeare WC, Fantin VR, Wang F et al. (2009) Discovery of potent and selective orally active inhibitors of anaplastic lymphoma kinase (ALK). Proceedings of the 100th annual meeting of the American association for cancer research (AACR), Denver, CO, 27-30 September 2010, abstract 3738
48. Rivera VM, Anjum R, Wang F et al. (2010) Efficacy and phar-macodynamic analysis of AP26113, a potent and selective orally active inhibitor of anaplastic lymphoma kinase (ALK). Pro-ceedings of the 101th annual meeting of the American association for cancer research (AACR), Washington, DC, 17-21 April 2010, poster 3623
49. Zhang S, Wang F, Keats J, Ning Y, Wardwell SD (2010) AP26113, a potent ALK inhibitor, overcomes mutations in EML4-ALK that confer resistance to PF-02341066 (PF1066). Proceedings of the 101th annual meeting of the American asso-ciation for cancer research (AACR), Washington, DC, 17-21 April 2010, poster LB-298
50. Rodig SJ, Mino-Kenudson M, Dacic S et al (2009) Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 15:5216-5223
51. Choi YL, Takeuchi K, Soda M et al (2008) Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68:4971-4976